Paz-Ares L, Dvorkin M, Chen Y, et al. - Researchers evaluated durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) for the treatment of patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) enrolled in the randomized, open-label, phase 3 CASPIAN trial. This investigation was conducted at 209 sites across 23 countries. Overall survival was assessed in the intention-to-treat population as the primary endpoint. The durvalumab plus platinum–etoposide group included 268 patients; the platinum–etoposide group included 269 patients. In patients with ES-SCLC, a significant improvement in overall survival was evident in relation to first-line treatment with durvalumab plus platinum–etoposide vs a clinically relevant control group. The observed safety findings were consistent with the acknowledged safety profiles of all drugs received.